Amid slumping diabetes sales and impending biosimilar competition for its star drug Lantus, Sanofi is shaking up its top management team for the second time since CEO Olivier Brandicourt took the helm last year.
The changes line up with the “strategic roadmap” Brandicourt unveiled last November, along with promises to revitalize Sanofi’s key diabetes business. They include a new position–as yet unfilled–running the consumer healthcare business, soon to be much larger, after the unit swap with Boehringer Ingelheim.
Then there’s the departure of Pascale Witz, who’s been running Sanofi’s diabetes and cardiovascular business since mid-2015. That unit’s sales slipped by 5.8% in the first quarter, dragged down by a big decline in Lantus sales.
That business has also been in an uncomfortable spotlight for a couple of years now, since Sanofi announced a disappointingly flat sales forecast for 2015. Then, last October, the French drugmaker said diabetes sales had dropped, and that it expected the decline to continue. Pricing pressure in the U.S., new competition, and Lantus biosimilars in Europe were already taking their toll.
The company had hoped to rev up some newly launched drugs–including its Lantus follow-up Toujeo–to help fill the gap when Lantus started facing biosimilar competition. But those rollouts didn’t all go as planned: The inhaled insulin Afrezza never got off the ground, and now Sanofi has dropped it altogether; Toujeo has struggled to gain basal insulin share, partly because of Lantus’ dominant position, partly on competition from other meds. The drug brought in €103 million in Q1, up only slightly from Q4’s €98 million.
In an emailed statement, Sanofi said that it’s premature to speculate on any upcoming changes in its diabetes business, after Guenter takes the reins.
Meanwhile, Sanofi’s new cholesterol drug Praluent, one of the closely watched PCSK9 drugs, isn’t churning out sales, either. The Sanofi and Regeneron med, along with Amgen’s competitor Repatha, are suffering as payers restrict their use and doctors remain skeptical about their ability to reduce cardiovascular risks in addition to dramatically lowering “bad” LDL cholesterol.
Now, Sanofi is in the thick of a hostile bid for U.S.-based cancer specialist Medivation. The deal would bring an immediate sales boost–Medivation’s prostate cancer med Xtandi is already a blockbuster–and pipeline candidates as well. And it would help amp up Sanofi’s oncology business, one of Brandicourt’s strategic aims. But several other Big Biopharmas are reportedly in the hunt as well, and Medivation has so far refused to engage with Sanofi about its $52.50-per-share bid.
By Tracy Staton
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
